Ginkgo Bioworks Holdings (DNA)

Healthcare · Biotechnology
$13.00 +14.64% on the day Market cap $762M 52-week range $5.37 to $18.22 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Ginkgo Bioworks Holdings's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from DNA's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation4
Profitability0
Growth0
Financial health6
Cash efficiency0

Results from SEC filings

Fiscal years, from Ginkgo Bioworks Holdings's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$314M$478M$251M$227M$170M
Net income-$1.8B-$2.1B-$893M-$547M-$313M
Free cash flow-$310M-$304M-$336M-$382M-$179M
EPS (diluted)-$55.60-$50.20-$18.37-$10.54-$5.64
Operating margin-582.6%-462.4%-343.8%-246.5%-185.3%

Where the revenue comes from

Revenue by segments, fiscal 2023. Every breakdown, year by year.

Cell Engineering$144M57%
Biosecurity$108M43%

Superinvestors who own DNA

From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Andreas Halvorsen
Viking Global Investors
Held $35M0.10%Q2 2026
Cliff Asness
AQR Capital Management
Added $6M0.00%Q2 2026

Insider buying

Open-market purchases by Ginkgo Bioworks Holdings's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of DNA in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when DNA trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Ginkgo Bioworks Holdings insiders buying the stock?

No open-market insider purchases of DNA in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Ginkgo Bioworks Holdings?

2 of the superinvestors Investingly tracks hold DNA in their latest 13F, including Andreas Halvorsen, Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.